|Videos|February 24, 2022
HSCT With Omidubicel Achieved Robust Immune Reconstitution and Lower Rates of Severe Infection Compared to UCB Transplantation
Author(s)Paul Szabolcs, MD
Expert hematologist/oncologist Paul Szabolcs, MD, reviews positive data from a clinical trial comparing hematopoietic stem cell transplantation and omidubicel with standard cord blood transplantation.
Advertisement
Paul Szabolcs, MD, discusses data from the following study:
- Hematopoietic Stem Cell Transplantation (HSCT) With Omidubicel Is Associated With Robust Immune Reconstitution and Lower Rates of Severe Infection Compared to Standard Umbilical Cord Blood [UCB] Transplantation (ASH 2021, Dec 11-14. Abstract 333)
- The objective of this study is to report the efficacy of HSCT with omidubicel as compared to standard umbilical cord blood transplantation in patients with hematologic malignancies.
- The limitations of cord blood transplantation are delayed hematopoietic and immune recovery and increased transplant-related mortality, although a robust recovery of NK [natural killer] cells is evident.
- Omidubicel is an advanced cell therapy for allogeneic HSCT that preserves stem cell function to optimize homing, engraftment, and differentiation.
- Conclusions:
- HSCT with omidubicel results in rapid hematopoietic recovery, reduced rates of infections, and no increase in GvHD [graft-versus-host disease] rates compared with standard UCB transplantation.
- In the immediate post-transplant period, immune cell recovery was significantly faster with omidubicel compared with standard UCB transplantation despite receiving a lower number of T cells at transplant.
- Enhanced recovery of circulatory mDC [myeloid dendritic cells], pDC [plasmacytoid dendritic cells], NK, and CD4+ T cells within the first 28 days, and sustained B-cell recovery from Day 28 through the first year, were observed.
- These results demonstrate rapid and functional reconstitution of T- and B-cell subsets following transplant with omidubicel, which provides mechanistic support for the lower rates of severe infection observed in the omidubicel-treated patients.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Advertisement
Related Articles
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025
- CGTLive®’s Weekly Rewind – September 12, 2025
September 12th 2025
- Around the Helix: Cell and Gene Therapy Company Updates – September 10, 2025
September 10th 2025
- CGTLive®’s Weekly Rewind – September 5, 2025
September 5th 2025
Advertisement
Advertisement